Clinical Trials in New York

Showing 5621-5640 of 17,259 trials

ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

NCT05532722

An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

T-cell Large Granular Lymphocytic Leukemia

Abcuro, Inc.21 participantsStarted Sep 2022

Duarte, California, United States • Los Angeles, California, United States • Boston, Massachusetts, United States +5 more locations

COMPLETEDPhase 1< 1 mile

A Study of LY3022855 In Participants With Breast or Prostate Cancer

NCT02265536

The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6 weeks).

NeoplasmsNeoplasm Metastasis

Eli Lilly and Company34 participantsStarted May 2015

Los Angeles, California, United States • New York, New York, United States

RECRUITINGPhase 2< 1 mile

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

NCT06284590

The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.

Melanoma Stage IIIMelanoma Stage IV

Philogen S.p.A.162 participantsStarted Jul 2024

New York, New York, United States

ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Find Trials by Condition in New York

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

HIPEC for Peritoneal Carcinomatosis

Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Diagnostic Precision and Accuracy Using the Teed Scoring System Versus the O'Neill Grading System

Reducing Urban Cervical Cancer Disparities

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms